Deepa J. Arachchillage

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

Hannah Cohen, Beverley J. Hunt, Maria Efthymiou et al. · The Lancet Haematology · 2016 · 393 citations · Full text

Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations

Brijesh Patel, Deepa J. Arachchillage, Carole A. Ridge et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 293 citations · Full text

Anti‐protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome

Deepa J. Arachchillage, Maria Efthymiou, Ian Mackie et al. · Journal of Thrombosis and Haemostasis · 2014 · 80 citations

Thrombosis, Medicine, Immunology +7

Should we abandon the APTT for monitoring unfractionated heparin?

Deepa J. Arachchillage, Farah Kamani, Simona Deplano et al. · Thrombosis Research · 2017 · 70 citations

Unfractionated Heparin, Hepatitis, Coagulopathy +2

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

Deepa J. Arachchillage, Ian Mackie, Maria Efthymiou et al. · Journal of Thrombosis and Haemostasis · 2015 · 59 citations

Thrombopoiesis, Thrombosis, Venous Thrombosis +10